Sökning: WFRF:(Hinkula Jorma 1958 ) >
DNA-VLP prime-boost...
-
Buonaguro, LViral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
(författare)
DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
- Artikel/kapitelEngelska2007
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2007
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-38564
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-38564URI
-
https://doi.org/10.1016/j.vaccine.2007.05.052DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:115758827URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
The immune response to HIV-1 virus-like particles (VLPs), presenting a clade A Ugandan gp120, has been evaluated in a mouse model by intra-nasal (i.n.) administration by a VLP + VLP homologous or a DNA + VLP heterologous prime-boost immunization protocol, including a HIV-1 DNA gp160/rev plasmid. Furthermore, the effect of the Eurocine lipid-based mucosal L3 adjuvant on the VLP immunogenicity has been assessed as well. The designed heterologous protocol is able to increase the env-specific humoral and cellular immune response, compared to the homologous protocol, which is to some extent increased by the administration of L3-adjuvanted VLP boosting dose. The anti-gag response is statistically increased in both homologous and heterologous protocols, particularly when the VLP boosting dose is adjuvanted. Immune sera from immunized animals exhibit >50% ex vivo neutralizing activity against heterologous A and B-clade viral isolates. An envelope B-cell epitope mapping shows an enhanced response against V3 epitopes all across the C2-V5 region in the heterologous prime-boost immunization strategy. The induction of humoral immunity at mucosal sites, which represents the main port of entry for the HIV-1 infection, is extremely relevant. In this framework, the DNA-VLP heterologous prime-boost protocol appears a promising preventive vaccine approach which can significantly benefit from specific mucosal adjuvants, as the Eurocine L3. © 2007 Elsevier Ltd. All rights reserved.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Devito, CLinköpings universitet,Molekylär virologi,Hälsouniversitetet
(författare)
-
Tornesello, MLViral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
(författare)
-
Schröder, UEurocine Vaccines AB, Sweden
(författare)
-
Wahren, BKarolinska Institutet
(författare)
-
Hinkula, Jorma,1958-Linköpings universitet,Hälsouniversitetet,Molekylär virologi(Swepub:liu)jorhi40
(författare)
-
Buonaguro, FMViral Oncogenesis and Immunotherapies & AIDS Reference Center, Italy
(författare)
-
Viral Oncogenesis and Immunotherapies & AIDS Reference Center, ItalyMolekylär virologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Vaccine: Elsevier BV25:32, s. 5968-59770264-410X1873-2518
Internetlänk
Hitta via bibliotek
-
Vaccine
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas